PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 20, 20261 citations

Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single-arm, phase 2 clinical trial.

View Full Paper
ZXZhehao XiaoZLZhongguo LiangHHHejing Huang

Key Points

  • To evaluate the antitumor efficacy and safety of toripalimab combined with concurrent chemoradiotherapy in recurrent nasopharyngeal carcinoma.
  • Single-arm, phase 2 clinical trial design
  • Administration of toripalimab alongside chemoradiotherapy
  • Assessment of treatment outcomes and adverse effects
  • Reported a 22.5% rate of fatal epistaxis
  • Demonstrated significant antitumor efficacy
  • Highlighting the need to balance treatment benefits against serious risks

Abstract

Toripalimab plus CCRT demonstrates antitumor efficacy in rNPC. The observed 22.5% rate of fatal epistaxis indicates that its potential benefits must be carefully weighed against this serious treatment-related risk.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xiao et al. (2026) studied this question.

synapsesocial.com/papers/696f1a629e64f732b51eeaabhttps://doi.org/10.1002/cncr.70257
Ask AI
Helpful
Bookmark
Share
View Full Paper